- The only insured DMB product with pure 100 % human tissue

- Just 10% prescription charge compared with other products

Starting in June, CG Bio (President Jeong Nam Young) will begin an orthopedics clinical test on ‘CGDBM 100,’ the first 100% DBM (Demineralized Bone Matrix) developed in Korea. DBM is a bond graft that removes mineralsfrom bond. This test is to verify its effectiveness in cervical vertebra and lumbar vertebra fusion. The clinical test shall be progressed in Samsung Seoul Hospital, Sinchon Severance Hospital and the Seoul National University hospital on patients with disc including spinal stenosis.



Of the DBM products, only CGDBM100 is covered by Korean medical insurance, which will reducethe financial burden of patients considerably. CG Bio said "Patients undergoing this operation pay just a 10% prescription charge compared with other non-applied DBM products, which dramatically reduces the financial burden of patients."

CGDBM100 has excellent osteanagenesis compared with other DBM products, as it has an outstanding amount of BMP-2, a protein promoting bone generation. Accordingly, it reduces the treatment period considerably. CG Bio uses patented technology to miniaturize DBM, making the viscosity of DBM itself suitable for operation.

CGDBM100 is looking forward to various clinical tests in the areas of dentistry and podiatry. A CB Bio spokesperson said, "If we are successful in clinical tests, it will help us to lay a foundation for advancing into Asia and developed countries, including the US. Previously, Korea was completely dependent on imports in this area, but now we can export DBM."